Sporadic, age-related cerebral amyloid angiopathy (CAA) is most commonly recognized clinically as a cause of hemorrhagic stroke and transient focal neurological episodes in older persons. But a growing body of research in the last 5 years shows that the pathophysiology of CAA is much more complex than previously believed, leading to many different types of brain injury. CAA has now been linked with brain atrophy in regions remote from those directly affected by intracerebral hematomas, and with risk for progressive cognitive decline in the absence of new hemorrhagic strokes. Therefore, CAA is associated with features -brain atrophy and progressive cognitive decline -that are typically considered hallmarks of neurodegenerative disease. Although CAA is usually accompanied by some degree of Alzheimer's disease pathology, the profiles of cortical thinning and cognitive impairment do not fully overlap with those seen in Alzheimer's disease, suggesting that there are CAA-specific pathways of neurodegeneration. CAA-related brain ischemia may be an important mechanism that leads to brain injury, cortical disconnection, and cognitive impairment.
Sporadic, age-related cerebral amyloid angiopathy (CAA) is caused by accumulation of beta-amyloid in the media and adventitia of small arteries in the cortex and leptomeninges (Vinters 1987) . For several decades it has been well known as a cause of lobar intracerebral hemorrhage (ICH) in older persons (Smith and Eichler 2006) . But a large and growing body of research in the last 5 years shows that CAA has diverse clinical manifestations, related to a multitude of types of brain injury (Charidimou et al. 2012; Boulouis et al. 2016) . This includes evidence that CAA is associated with atrophy and cognitive decline Case et al. 2016; Xiong et al. 2016) in the absence of clinically symptomatic stroke. In light of this new evidence, it is now appropriate to consider whether CAA is a neurodegenerative disease, as well as a common cause of stroke. This review summarizes evidence linking CAA with progressive cognitive decline and brain atrophy, also pointing to potential mechanisms for the neurodegeneration seen in CAA.
What is neurodegeneration?
The terms 'neurodegeneration' and 'neurodegenerative' are widely used but without a formal definition in the peerreviewed literature. The terms are frequently used to refer to a group of neurological conditions marked by death of neurons and supporting cells in the neurovascular unit, with accompanying progressive loss of cognitive and motor functions. The commonest conditions described as neurodegenerative are Alzheimer's disease (AD) dementia and related disorders, and Parkinson's disease and other progressive movement disorders. From a neuroimaging and gross pathological viewpoint, these disorders are marked by regional or global brain atrophy resulting from progressive cell death.
Stroke and other forms of monophasic acute brain injury (e.g., because of trauma) are not typically considered to be neurodegenerative disorders. Therefore, CAA is most commonly conceptualized as a cerebrovascular disease associated with risk of lobar ICH, and not as a cause of neurodegeneration. However, accruing evidence suggests that CAA is not so easy to pigeonhole as either a cause of stroke or neurodegeneration, but instead is an important cause of both of these neurological syndromes. To make my case that CAA should be considered a neurodegenerative disease, I focus on associations between CAA and two cardinal features of neurodegenerative diseases: cognitive decline and brain atrophy.
CAA is associated with high risk for progressive cognitive decline
Two large, single-center cohort studies show that nondemented lobar ICH survivors, many or most of whom have CAA, are at high risk for incident dementia even in the absence of new ICHs (Biffi et al. 2016; Moulin et al. 2016) . These studies were inception cohorts of survivors recruited at 6 months after their index ICH, verified to be free of dementia at this time, and followed prospectively over time for incident dementia events.
In a study of 560 ICH patients recruited in Lille, France, the investigators found that roughly 30% of non-demented lobar ICH survivors had developed incident dementia by 36 months (Moulin et al. 2016) . The dementia risk was associated with many neuroimaging features associated with CAA, including lobar ICH location, the presence of additional lobar microbleeds, and cortical superficial siderosis.
In the other study of 738 ICH survivors recruited in Boston, USA, the overall (i.e., combining lobar and nonlobar ICH) 3-year incident dementia risk was roughly 17% (Biffi et al. 2016) . The hazard for incident dementia was 1.78-fold higher in the patients with lobar microbleeds -that is, in a similar range as that observed for lobar ICH survivors in the Lille cohort.
An example case from the author's practice is shown in Fig. 1 . This 78-year-old man presented with mild aphasia because of a left parietal lobar ICH. Over the next 2 years, there was progressive cognitive impairment and loss of daily activities of living leading to a diagnosis of mild dementia, in the absence of new ICHs.
CAA is associated with brain atrophy
A recent publication shows that CAA is associated with thinning of the cerebral cortex in areas that are remote from focal damage from lobar ICHs . In this study, high-resolution T1-weighted MR in 63 patients with age-related CAA was compared to neurologically asymptomatic healthy controls. Manual edits were used to exclude brain regions directly affected by encephalomalacia from prior ICHs. Thinning of the cortex was observed in multiple brain regions (Fig. 2) . A similar pattern was seen in 26 patients with a hereditary form of CAA caused by a mutation in the amyloid precursor protein .
In another study, the same author group used a different magnetic resonance imaging (MRI) processing method to show that smaller brain volumes in CAA patients were associated with slower cognitive processing speed and worse executive functions (Xiong et al. 2016) .
Is neurodegeneration in CAA solely a function of concomitant AD pathology?
Atrophy and cognitive impairment in CAA could result from either of three pathways, or a combination: a) the direct effects of tissue destruction by ICHs, b) the effects of concomitant AD pathology, or c) pathomechanisms other than ICH or AD (Fig. 3) .
The potential contribution from AD pathology must be considered, because AD and CAA are sister diseases that share important aspects of their pathogenesis. Both are a consequence of cleavage of the amyloid precursor protein to form pathogenic Ab which aggregates into b-amyloid. In the case of AD pathology, the b-amyloid aggregates in the brain parenchyma in the form of neuritic plaques. In the case of CAA, the b-amyloid aggregates in the walls of small arteries and arterioles. Most patients with CAA also have some degree of neuritic plaques, and most patients with AD have some degree of CAA (Brenowitz et al. 2015) .
However, there are also important contrasts between the two diseases ( Table 1) . The beta-amyloid in CAA contains a higher proportion of Ab1-40 compared to the beta-amyloid neuritic plaques (Thal et al. 2008) . While the apolipoprotein E (ApoE) e4 allele is a risk factor for both CAA and AD, the e2 allele does not appear to protect against CAA and in fact may be associated with more severe vasculopathic changes .
Although AD and CAA appear to exist on a spectrum and have shared molecular mechanisms, the clinical features differ such that symptomatic patients tend to exhibit either a CAA syndrome, marked by ICHs and transient focal neurological episodes, or an AD syndrome, marked by progressive cognitive decline. Once on the AD path, it seems that there is not much crossover to the CAA syndrome clinically. It is rare for patients with AD-dementia to later develop lobar ICHs, even though MRI evidence of asymptomatic microbleeds is common (Pettersen et al. 2008) . The typical end stage of AD is terminal dementia, not fatal ICHs.
But could CAA patients be at high risk for developing dementia as a result of AD? This is possible. However, in CAA the patterns of cognitive impairment and atrophy have features that are not always consistent with AD.
The cognitive profile of patients with CAA has been investigated in two single-center cross-sectional studies (Case et al. 2016; Xiong et al. 2016) . Both studies included only non-demented patients with CAA. The results were concordant in that both studies showed a high prevalence of mild cognitive impairment, with prominently impaired performance on timed tasks and on tasks of executive function. The one study that compared CAA patients to those with AD-dementia found that episodic memory was relatively less impaired in CAA (Case et al. 2016) . Thus, the average cognitive profile of CAA patients appears to be more similar to the profile of vascular cognitive impairment (Sachdev et al. 2014) than AD.
The pattern of cortical thinning in CAA ) overlaps with AD (Dickerson et al. 2009 ) in some regions (supramarginal gyrus, superior frontal gyrus, and inferior temporal gyrus), but other regions exhibit more thinning in CAA than AD (occipital cortex and medial frontal cortex) or in AD than CAA (precuneus, angular gyrus, and anterior temporal cortex) (Fig. 2) . Overall, there are clear differences between the CAA and AD patterns of cortical thinning.
These differences in cognitive profile and regional cortical thinning suggest that neurodegeneration in CAA cannot be solely attributed to the effects of concomitant AD pathology. Unfortunately, in vivo amyloid markers do not distinguish CAA from AD with high accuracy. The amyloid positron emission tomography ligands Pittsburgh compound B and florbetapir bind to vascular amyloid as well as parenchymal amyloid (Ducharme et al. 2013; Gurol et al. 2016) . Cerebrospinal fluid Ab42 is low in CAA as well as AD (Renard et al. 2016; Shams et al. 2016) . Although mean Ab40 levels may be lower (Verbeek et al. 2009; Renard et al. 2016 ) and occipital amyloid positron emission tomography retention Fig. 1 Example of a patient with cerebral amyloid angiopathy and an intracerebral hemorrhage who developed new dementia. A 77-year-old man presented with a left parietal intracerebral hemorrhage (CT) with mild aphasia. MRI GRE showed lobar microbleeds (example is shown by the arrow) consistent with probable cerebral amyloid angiopathy. MRI FLAIR showed extensive, confluent white matter hyperintensities of presumed vascular origin. Over the next 2 years, he developed progressive cognitive decline to dementia in the absence of new symptomatic hemorrhages, with worsening performance on tasks of executive function including the Trail Making test, evident as increasing time needed to complete the Trail Making B task but not the Trail Making A task. FDG-PET showed hypometabolism in the left parietal lobe near the location of the prior intracerebral hemorrhage (arrow), but also patchy hypometabolism in regions of the frontal lobes (arrows). This case illustrates progressive cognitive decline in cerebral amyloid angiopathy without new hemorrhages, with a pattern of cognitive impairment and distribution of glucose hypometabolism atypical for Alzheimer's disease and more consistent with vascular cognitive impairment. CT, computed tomography; MRI GRE, magnetic resonance imaging gradient-recalled echo; MRI FLAIR, magnetic resonance imaging fluid-attenuated inversion recovery; FDG-PET, fluoro-deoxyglucose positron emission tomography. may be higher (Johnson et al. 2007) in CAA than AD, no cut-offs have been published that discriminate CAA from AD with high sensitivity and specificity.
In AD patients, the presence of lobar microbleeds suggests concomitant CAA, but is probably not a very sensitive indicator. In other words, the pathological prevalence of CAA in AD patients (more than 80%, with 25% having severe CAA; Ellis et al. 1996 ) is higher than the prevalence of lobar microbleeds (about 20-30%; Pettersen et al. 2008; Noguchi-Shinohara et al. 2017) . Compared to AD patients without microbleeds, AD patients with microbleeds in only lobar brain locations have lower mean CSF Ab40 and Ab42 levels, lower temporal glucose metabolism, and more atrophy of the temporal gray matter and cerebellum (Samuraki et al. 2015; Noguchi-Shinohara et al. 2017) . Therefore, these changes may mark AD patients with higher levels of accompanying CAA.
In sum, it is currently not possible to accurately determine the relative amounts of CAA and AD in individual patients in vivo. This limits efforts to attribute specific cognitive and atrophy profiles to pure CAA, pure AD, or mixed pathology.
More direct evidence for an independent effect of CAA pathology on cognition comes from community-based autopsy studies, where AD and CAA pathology can be quantified and evaluated as independent predictors of antemortem cognitive function in regression models. In these studies, CAA has emerged as predictor of cognitive decline and increased risk for dementia controlling for AD pathology (Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS) (2001), Pfeifer et al. 2002; Boyle et al. 2015; Arvanitakis et al. 2011) .
Thus, it appears likely that neurodegeneration in CAA cannot be entirely accounted for by AD pathology, and must involve other mechanisms.
Non-AD pathomechanisms of neurodegeneration in CAA
Recognized initially as a cause of ICH, there are now a host of additional pathological and radiological markers of CAArelated brain injury including microbleeds, cortical superficial siderosis, dilated perivascular spaces, microinfarcts, white matter hyperintensities of presumed vascular origin, lacunes, CAA-related inflammation, increased white matter diffusivity, and decreased white matter connectivity. Some of these injuries may contribute to neurodegeneration.
Based on our improved understanding of the cerebral consequences of CAA pathology, a hypothetical model of how CAA-related brain injury leads to neurodegeneration can be postulated (Fig. 4 ). This hypothetical model proposes two main pathways: an ischemic pathway leading to microinfarction and ischemic demyelination, and a hemorrhagic pathway leading to bleeding events. These pathways converge to cause gray and white matter atrophy, disconnecting brain networks.
There is growing appreciation that ischemic brain injury, including white matter lesions and microinfarcts, are frequent in CAA . In both animal (Shin et al. 2007; Han et al. 2008; Park et al. 2014 ) and human (Smith et al. 2008; Dumas et al. 2012; Peca et al. 2013 ) studies of CAA, there is markedly impaired vasodilation despite relatively normal resting blood flow (Dumas et al. 2012) . In humans, this impairment in vasodilation can be observed as decreased blood oxygen level dependent signal changes during task-based functional MRI (Dumas et al. 2012; Peca et al. 2013) . The impaired capacity to vasodilate may lead to intermittent episodes of local ischemia when cerebral perfusion pressure is low or blood flow demand is high. In the white matter, this may lead to ischemic demyelination visible on MRI as white matter hyperintensities of presumed vascular origin. In the cortical gray matter, which may be less susceptible to ischemia because of a richer network of collateral vessels than the white matter, intermittent reduction in blood flow could nonetheless lead to microinfarction. Alterations in vascular reactivity appear early in CAA and are progressive (Switzer et al. 2016; van Opstal et al. 2017) . A study of presymptomatic Dutch CAA mutation carriers found that they exhibited abnormal functional magnetic resonance imaging responses at an early stage of disease, prior to the onset of symptomatic hemorrhages, cognitive impairment, or neuroimaging evidence of brain atrophy (van Opstal et al. 2017) . Thus, impaired vasodilation precedes evidence of neurodegeneration and may cause it.
Loss of vascular integrity with hemorrhaging has been the longest recognized clinical manifestation of CAA (Smith and Eichler 2006) . Large, destructive hematomas can certainly cause cognitive impairment. Whether microbleeds can cause Samuraki et al. 2015) although whether microbleeds directly cause the impairment or are merely a marker of small vessel disease is unclear. In CAA, existing evidence suggests that cognitive impairment and atrophy are not strongly related to microbleed counts (Case et al. 2016; Xiong et al. 2016) which instead are more strongly associated with future ICH risk (Greenberg et al. 2004) . If microbleeds and superficial siderosis do cause neurodegeneration, one mechanism may be iron toxicity (Ward et al. 2014) , resulting from the breakdown of the hemoglobin molecule in extravasated red blood cells. There may be additional factors that cross both pathways, ischemic and hemorrhagic. As with most diseases inflammation may play a complex role, both promoting recovery but also conferring a risk for bystander injury. Rarely, patients present with overt CAA-related inflammation (CAAri), marked by perivascular inflammation or vasculitis with white matter edema (Kinnecom et al. 2007 ). However, the degree to which intermittent or low grade inflammation contributes to CAA-related neurodegeneration is unclear.
Disconnection of cortical regions, with altered structure of brain networks, is strongly associated with cognitive function and cortical thinning in CAA (Reijmer et al. 2015 (Reijmer et al. , 2017 . This disconnection may represent a common outcome of converging pathways of injury that ultimately mediates much of the cognitive dysfunction seen in CAA patients.
Conclusions
CAA is associated with hallmark features of neurodegeneration, atrophy, and cognitive dysfunction, even in the absence of new large, destructive hematomas. Therefore, CAA should be considered a neurodegenerative disease as well as a cerebrovascular disease.
Future research on CAA and neurodegeneration should include studies to identify predictors of cognitive decline, to discover pathomechanisms of atrophy and cognitive decline including new diagnostic and monitoring markers, to determine whether cognitive enhancing drugs for AD also improve cognition in CAA, and to identify new opportunities for treatment. This research would be greatly accelerated by the development of in vivo markers that can discriminate the load of vascular versus parenchymal amyloid with high sensitivity and specificity, so that accurate measurements of CAA and AD pathology in living individuals becomes feasible.
Clinicians should be aware that patients with CAA often have cognitive concerns. Patients without dementia frequently have mild cognitive impairment. Patients with CAA, including survivors of lobar ICH and patients with transient focal neurological episodes, should be questioned regarding cognitive concerns. When concerns are expressed by patients, caregivers, or evident to the clinician, they should be followed by cognitive testing, at minimum to include a cognitive screening evaluation such as the Montreal Cognitive Assessment tool (Nasreddine et al. 2005) . It seems appropriate to monitor patients with CAA every 6-12 months for new cognitive concerns or worsening.
